Dr. Baoxing Liu 刘宝兴
Chief Physician, Associate Professor
Department of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and comprehensive treatment of esophageal cancer, lung cancer, and mediastinal tumors. Minimally invasive surgery for benign esophageal conditions, including gastroesophageal reflux disease and achalasia.
Dr. Liu holds a PhD and serves as Chief Physician and Associate Professor. Research involvement includes the National 11th Five-Year Science and Technology Key Project and multiple National Natural Science Foundation projects. Dr. Liu participated in a provincial project on apoptosis signaling in non-small cell lung cancer and has published 20 papers, with 16 indexed by SCI.
Professional roles
- Youth Committee Member, Esophageal Cancer Professional Committee, Henan Anti-Cancer Association
- Youth Committee Member, Lung Cancer Professional Committee, Henan Anti-Cancer Association
Name order: in Chinese the family name comes first (Liu Baoxing). Papers usually list the name as Baoxing Liu or Liu B.
Selected publications
15 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2024 (first author): Effect of sternocleidomastoid flap repair and endoscopic injection of emulsified adipose tissue stromal vascular fraction in the treatment of refractory cervical anastomotic leak contaminating mediastinum. PubMed 38738227
- Front Oncol, 2024 (first author): A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study. PubMed 38414743
- Cell Cycle, 2023 (first author): CircSCN8A suppresses malignant progression and induces ferroptosis in non-small cell lung cancer by regulating miR-1290/ACSL4 axis. PubMed 36482742
- Am J Cancer Res, 2022 (senior author): Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer. PubMed 35812062
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion